Milford Molecular Diagnostics, Milford, CT 06460, USA.
School of Biological, Earth and Environmental Sciences, University College Cork, T23 N73K Cork, Ireland.
Int J Environ Res Public Health. 2019 May 20;16(10):1779. doi: 10.3390/ijerph16101779.
Lyme disease, initially described as Lyme arthritis, was reported before nucleic-acid based detection technologies were available. The most widely used diagnostic tests for Lyme disease are based on the serologic detection of antibodies produced against antigens derived from a single strain of . The poor diagnostic accuracy of serological tests early in the infection process has been noted most recently in the 2018 Report to Congress issued by the U.S. Department of Health and Human Services Tick-Borne Disease Working Group. Clinical Lyme disease may be caused by a diversity of borreliae, including those classified as relapsing fever species, in the United States and in Europe. It is widely accepted that antibiotic treatment of Lyme disease is most successful during this critical early stage of infection. While genomic sequencing is recognized as an irrefutable direct detection method for laboratory diagnosis of Lyme borreliosis, development of a molecular diagnostic tool for all clinical forms of borreliosis is challenging because a "core genome" shared by all pathogenic borreliae has not yet been identified. After a diligent search of the GenBank database, we identified two highly conserved segments of DNA sequence among the borrelial 16S rRNA genes. We further developed a pair of genus-specific PCR primers for amplification of a segment of borrelial 16S rRNA gene as a "core genome" to be used as the template for routine Sanger sequencing-based metagenomic direct detection test. This study presented examples of base-calling DNA sequencing electropherograms routinely generated in a clinical diagnostic laboratory on DNA extracts of human blood specimens and ticks collected from human skin bites and from the environment. Since some of the tick samples tested were collected in Ireland, borrelial species or strains not known to exist in the United States were also detected by analysis of this 16S rRNA "core genome". We recommend that hospital laboratories located in Lyme disease endemic areas begin to use a "core genome" sequencing test to routinely diagnose spirochetemia caused by various species of borreliae for timely management of patients at the early stage of infection.
莱姆病,最初被描述为莱姆关节炎,在核酸检测技术出现之前就已经有报道。目前最广泛使用的莱姆病诊断检测方法是基于对来自单一菌株的抗原产生的抗体进行血清学检测。美国卫生与公众服务部 tick-borne disease working group 在 2018 年向国会提交的报告中,最近指出了在感染早期血清学检测准确性差的问题。在美国和欧洲,临床莱姆病可能由多种伯氏疏螺旋体引起,包括分类为回归热螺旋体的物种。人们普遍认为,在感染的这个关键早期阶段,抗生素治疗莱姆病最成功。虽然基因组测序被认为是实验室诊断莱姆螺旋体病的一种不可否认的直接检测方法,但开发一种针对所有临床形式伯氏疏螺旋体病的分子诊断工具具有挑战性,因为尚未确定所有致病性伯氏疏螺旋体共享的“核心基因组”。在对 GenBank 数据库进行了仔细搜索后,我们在伯氏疏螺旋体 16S rRNA 基因中发现了两个高度保守的 DNA 序列片段。我们进一步开发了一对属特异性 PCR 引物,用于扩增伯氏疏螺旋体 16S rRNA 基因的一段作为“核心基因组”,作为基于常规 Sanger 测序的宏基因组直接检测试验的模板。本研究展示了在临床诊断实验室中,从人类血液样本和从人类皮肤咬伤和环境中采集的蜱虫 DNA 提取物中,常规生成的碱基调用 DNA 测序电泳图谱的示例。由于测试的一些蜱样本是在爱尔兰采集的,因此通过分析这个 16S rRNA“核心基因组”,也检测到了在美国不存在的伯氏疏螺旋体物种或菌株。我们建议位于莱姆病流行地区的医院实验室开始使用“核心基因组”测序试验,常规诊断各种伯氏疏螺旋体引起的螺旋体血症,以便在感染早期及时管理患者。